Lyka Labs
94.07
+0.47(+0.50%)
Market Cap₹335.70 Cr
PE Ratio43.84
IndustryHealthcare
Company Performance:
1D+0.50%
1M-0.93%
6M-13.17%
1Y-39.63%
5Y+454.99%
View Company Insightsright
More news about Lyka Labs
08Aug 25
NCLT Reserves Order on Lyka Labs-Lyka Exports Merger, Signals No Objection
The National Company Law Tribunal (NCLT) Ahmedabad Bench has reserved its order on the proposed merger between Lyka Labs Limited and Lyka Exports Limited. During the hearing on August 7, 2025, the NCLT indicated 'no objection' to the scheme of amalgamation. Lyka Labs, the transferee company, awaits formal pronouncement of the order. The company's Managing Director & CEO, Kunal Gandhi, stated that necessary disclosures will be made once the NCLT order is formally pronounced.
01Aug 25
Lyka Labs Announces Q1 Results, Management Changes, and New Internal Auditor Appointment
Lyka Labs Limited has approved unaudited financial results for Q1 FY2025-26. The company secretary, Mr. Shekhar R Singh, has resigned effective August 1, 2025. Sudit K Parekh & Co. LLP has been appointed as the new internal auditor for FY2025-26, effective August 1, 2025.
01Aug 25
Lyka Labs Approves Q1 Results, Announces Key Management Changes
Lyka Labs Limited has approved its unaudited financial results for Q1 FY2025-26. The company's Company Secretary, Mr. Shekhar R Singh, has resigned effective August 1, 2025. Sudit K Parekh & Co. LLP has been appointed as the Internal Auditor for FY2025-26. These decisions were made during a Board meeting held on August 1, 2025.
26May 25
Lyka Labs Reports Improved Q4 EBITDA and Margin, Swings to Profit as Revenue Surges
Lyka Labs reported a net profit of ₹18 million in Q4, reversing a ₹21 million loss from the previous year. Revenue grew by 20% year-over-year to ₹334 million. EBITDA increased to ₹41 million from ₹20 million, with the EBITDA margin improving to 12.23% from 7.31%. Despite a slight decrease from Q3's profit of ₹27 million, the company maintains profitability.
08Apr 25
Lyka Labs Secures Indian Patent for Innovative Pregabalin Gel 8%
Lyka Labs Limited has been granted a patent by the Patent Office India for Pregabalin Gel 8%, a novel topical solution for managing diabetic neuropathic pain. The patent extends protection until 2043. The product, first of its kind in India, received CDSCO approval in October 2024 and was launched in December 2024. Lyka Labs has partnered with Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare for manufacturing and marketing the gel through P2P licenses.
Lyka Labs
94.07
+0.47
(+0.50%)
1 Year Returns:-39.63%
Industry Peers
Sun Pharmaceutical
1,691.40
(+0.33%)
Divis Laboratories
6,656.50
(-3.30%)
Cipla
1,505.70
(+0.28%)
Torrent Pharmaceuticals
3,580.00
(+0.75%)
Dr Reddys Laboratories
1,205.40
(+0.02%)
Zydus Life Science
944.10
(+0.79%)
Mankind Pharma
2,261.80
(-2.05%)
Lupin
1,971.80
(+0.83%)
Alkem Laboratories
5,668.50
(+0.44%)
Aurobindo Pharma
1,123.80
(-1.47%)